Skip Navigation
NIH Fibroid Treatment Study NIH Fibroid Treatment Study NIH Fibroid Treatment Study
NICHD
NIH Fibroid Treatment Study NIH Fibroid Treatment Study NIH Fibroid Treatment Study
Home General Information What This Study Involves Eligibility Criteria Contact Us Other Resources
spacer

Criteria

Inclusion Criteria

  • Good health. Chronic medication use is acceptable except for glucocorticoid use. Other chronic medication use may be acceptable at the discretion of the research team. Use of over-the counter drugs is acceptable but must be recorded.
  • Menstrual cycles of 24 – 35 days
  • Hemoglobin > 10 g/dL
  • Willing and able to comply with study requirements
  • Age 33 to 50
  • Using mechanical (condoms, diaphragms), sterilization or abstinence methods of contraception for the duration of the study
  • Negative urine pregnancy test
  • BMI (body mass index) < 30. This is calculated by dividing the weight in kilograms by the height in meters, squared
  • Able to read and speak English fluently to allow accurate self-administration of medication, recording of symptoms and unassisted completion of questionnaire
  • Normal kidney and liver function
  • History of uterine leiomyoma at least 2 cm in size causing symptoms of bleeding, pressure, or pain, as defined by the ACOG practice bulletin (ACOG Practice Bulletin 1994)
  • Excessive uterine bleeding will be evidenced by either of the following—profuse bleeding with flooding or clots or repetitive periods lasting for more than 8 days; or anemia due to acute or chronic blood loss OR
  • Pelvic discomfort caused by leiomyomata, either acute and severe or chronic lower abdominal or low back pressure or bladder pressure with urinary frequency not due to urinary tract infection
  • No desire for fertility; willing to undergo hysterectomy

Exclusion Criteria

  • Significant abnormalities in the history, physical or laboratory examination
  • Pregnancy or breast feeding
  • Use of oral, injectable or inhaled glucocorticoids (steroids) or megesterol within the last year
  • Unexplained vaginal bleeding
  • History of malignancy within the past 5 years
  • Use of any estrogen or progesterone-containing compounds, such as oral contraceptives and hormone replacement therapy, within 8 weeks of study entry
  • Use of certain drugs that affect liver function
  • Current use of GnRH analogs or other compounds that affect menstrual cyclicity
  • FSH > 20 IU/mL